Please assess the completion status of the following clinical trial:

Trial Title: Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients eligible for autologous stem cell transplant for multiple myeloma; planned use of filgrastim (GCSF) for stem cell mobilization~* Ability to give informed consent~* Glomerular filtration rate (GFR) \> 30 ml/minute~* Liver function tests \< 2.5 x upper limit of normal (ULN)~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 or less~* Based on prior therapy patients will be classified into two categories:~  * Initial mobilizers with no exposure to alkylators~ * Remobilizers or with prior exposure to alkylators or with greater than 5 cycles of lenalidomide therapy prior to mobilization~Exclusion Criteria:~* Use of a monoamine oxidase inhibitor (MAO-I) during or within 2 weeks of desipramine therapy~* Concomitant therapy with any drugs shown to have major interactions with desipramine~* Concurrent use of drugs that are contraindicated with desipramine~* Myocardial infarction in preceding 4 weeks; history of uncontrolled cardiac arrhythmias or family history of sudden cardiac death; baseline corrected QT (QTc) \> 460 msec~* Active alcohol abuse~* Bipolar disorder~* Untreated active major depression~* History of seizures in the past 3 years~* Pregnancy and lactation; refusal to use adequate contraception~* Uncontrolled thyroid disease~* GCSF or pegfilgrastim use within 14 days prior to enrollment~* Bortezomib, Revlimid or thalidomide use within 7 days of enrollment~* Patients with sickle cell disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (desipramine, filgrastim) (Type: EXPERIMENTAL): Participants received desipramine hydrochloride PO daily on days -3 to +4 and filgrastim PO BID on days 1-4. Stem cell collection began on day 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).